1. Recent developments in the medicinal chemistry of single boron atom-containing compounds
- Author
-
Shu Song, Vasanthanathan Poongavanam, Peng Zhan, Jacob Kongsted, Lin Sun, Xinyong Liu, Ping Gao, and Dongwei Kang
- Subjects
Mcl-1, myeloid cell leukemia 1 ,MTB - Mycobacterium tuberculosis ,SARS-CoV-2, syndrome coronavirus 2 ,BNNPs, boron nitride nanoparticles ,TB, tuberculosis ,OPs, organophosphate ,RA, rheumatoid arthritis ,Review ,OBORT, oxaborole tRNA capture ,0302 clinical medicine ,ADCs, Acinetobacter-derived cephalosporinases ,LeuRS, leucyl-tRNA synthetase ,BNNTs, boron nitride nanotubes ,MBLs, metal β-lactamases ,GSH, glutathione ,CIA, collagen-induced arthritis ,General Pharmacology, Toxicology and Pharmaceutics ,Prodrug ,AML, acute myeloid leukemia ,HADC1, class I histone deacetylase ,COVID-19, coronavirus disease 2019 ,0303 health sciences ,AMT, aminopterin ,cUTI, complex urinary tract infection ,Chemistry ,Drug discovery ,MM, multiple myeloma ,SERD, selective estrogen receptor downregulator ,Biological activity ,Hbv hepatitis b virus ,NA, neuraminidase ,NS5B, non-nucleoside polymerase ,HIV, human immunodeficiency virus ,SBLs, serine β-lactamases ,QM, quinone methide ,HCV, hepatitis C virus ,030220 oncology & carcinogenesis ,U4CR, Ugi 4-component reaction ,ClpP, casein protease P ,inorganic chemicals ,Linker components ,BNCT, boron neutron capture therapy ,PPI, protein–protein interaction ,Boron-containing compounds ,Mtb, Mycobacterium tuberculosis ,RM1-950 ,Covalent inhibitors ,03 medical and health sciences ,MDR-TB, multidrug-resistant tuberculosis ,ROS, reactive oxygen species ,Hcv hepatitis c virus ,PDB, Protein Data Bank ,ACTs, artemisinin combination therapies ,MTX, methotrexate ,PBA, phenylboronic acid ,030304 developmental biology ,TTR, transthyretin ,dCTPase, dCTPase pyrophosphatase ,CEs, carboxylesterases ,MERS, Middle East respiratory syndrome ,Binding properties ,BLs, β-lactamases ,Boron atom ,Combinatorial chemistry ,HBV, hepatitis B virus ,SHA, salicyl hydroxamic acid ,SaClpP, Staphylococcus aureus caseinolytic protease P ,MIDA, N-methyliminodiacetic acid ,MTX - Methotrexate ,Therapeutics. Pharmacology - Abstract
Various boron-containing drugs have been approved for clinical use over the past two decades, and more are currently in clinical trials. The increasing interest in boron-containing compounds is due to their unique binding properties to biological targets; for example, boron substitution can be used to modulate biological activity, pharmacokinetic properties, and drug resistance. In this perspective, we aim to comprehensively review the current status of boron compounds in drug discovery, focusing especially on progress from 2015 to December 2020. We classify these compounds into groups showing anticancer, antibacterial, antiviral, antiparasitic and other activities, and discuss the biological targets associated with each activity, as well as potential future developments., Graphical abstract Boron derivatives are playing an increasingly important role on drug discovery campaigns. Here, we reviewed the use and pharmacological properties of boronic acids as therapeutic agents for various diseases.Image 1
- Published
- 2021
- Full Text
- View/download PDF